Brought to you by 
Series B round brings Nimbus $43mm
16 Feb 2017
Executive Summary
Pfizer Venture Investments and Lightstone Venture led an oversubscribed $43mm Series B round for Nimbus Therapeutics (formerly Nimbus Discovery; combines computer-aided drug design, chemistry, and pharmacology to discover small molecules for various diseases). Returning backers Atlas Venture, SR One, Lilly Ventures, and Bill Gates participated. Nimbus will use the money to enter its lead acetyl CoA carboxylase (ACC) inhibitor into human testing for nonalcoholic steatohepatitis (NASH). Phase I data is expected later this year.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
- Bioinformatics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B round brings Nimbus $43mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice